HCW Biologics ( (HCWB) ) has shared an announcement.
On February 3, 2025, HCW Biologics announced that the FDA has cleared its Investigational New Drug Application for HCW9302, allowing the company to proceed with a Phase 1 clinical trial in patients with moderate to severe alopecia areata. This trial marks a significant milestone for the company, aiming to establish a safe dose of HCW9302, which leverages a novel IL-2 fusion protein to activate Treg cells, potentially transforming treatments for autoimmune diseases while minimizing immunosuppression.
More about HCW Biologics
HCW Biologics Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on developing innovative immunotherapies to combat diseases associated with chronic inflammation, particularly age-related and senescence-associated conditions. The company utilizes proprietary platform technologies, including TOBI and TRBC, to create novel immunotherapeutic compounds targeting autoimmune diseases, cancer, and other conditions impacting quality of life.
YTD Price Performance: -38.50%
Average Trading Volume: 9,935,357
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $10.52M
See more data about HCWB stock on TipRanks’ Stock Analysis page.